CA2182483A1 - Il-3 variant hematopoiesis fusion protein - Google Patents

Il-3 variant hematopoiesis fusion protein

Info

Publication number
CA2182483A1
CA2182483A1 CA002182483A CA2182483A CA2182483A1 CA 2182483 A1 CA2182483 A1 CA 2182483A1 CA 002182483 A CA002182483 A CA 002182483A CA 2182483 A CA2182483 A CA 2182483A CA 2182483 A1 CA2182483 A1 CA 2182483A1
Authority
CA
Canada
Prior art keywords
variant
hematopoiesis
fusion protein
hil
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002182483A
Other languages
French (fr)
Other versions
CA2182483C (en
Inventor
S. Christopher Bauer
Mark Allen Abrams
Sarah Ruth Braford-Goldberg
Maire Helena Caparon
Alan Michael Easton
Barbara Kure Klein
John Patrick Mckearn
Peter O. Olins
Kumnan Paik
John Warren Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2182483A1 publication Critical patent/CA2182483A1/en
Application granted granted Critical
Publication of CA2182483C publication Critical patent/CA2182483C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Abstract

The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
CA002182483A 1994-02-04 1995-01-25 Il-3 variant hematopoiesis fusion protein Expired - Fee Related CA2182483C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/192,299 US5738849A (en) 1992-11-24 1994-02-04 Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US08/192,299 1994-02-04
PCT/US1995/000549 WO1995021197A1 (en) 1994-02-04 1995-01-25 Il-3 variant hematopoiesis fusion protein

Publications (2)

Publication Number Publication Date
CA2182483A1 true CA2182483A1 (en) 1995-08-10
CA2182483C CA2182483C (en) 2002-04-02

Family

ID=22709107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002182483A Expired - Fee Related CA2182483C (en) 1994-02-04 1995-01-25 Il-3 variant hematopoiesis fusion protein

Country Status (13)

Country Link
US (4) US5738849A (en)
EP (2) EP1323737A3 (en)
JP (1) JPH09508524A (en)
AT (1) ATE237641T1 (en)
AU (1) AU700220B2 (en)
CA (1) CA2182483C (en)
DE (1) DE69530374T2 (en)
DK (1) DK0742796T3 (en)
ES (1) ES2197191T3 (en)
HK (1) HK1013655A1 (en)
NZ (1) NZ279624A (en)
PT (1) PT742796E (en)
WO (1) WO1995021197A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JPH11510062A (en) * 1995-10-05 1999-09-07 ジー．ディー．サール アンド カンパニー Multifunctional hematopoietic receptor agonist
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
CN1234073A (en) * 1996-10-25 1999-11-03 G·D·瑟尔公司 Circularly permuted erythropoietin receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
RU2245887C2 (en) * 1996-10-25 2005-02-10 Джи. Ди. Сирл Энд Ко. Hemopoietic protein (variants), dna sequence, method for preparing hemopoietic protein, method for selective expansion of hemopoietic cells, method for producing dendritic cells, method for stimulating for producing hemopoietic cells in patient, pharmaceutical composition, method for treatment
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ATE329622T1 (en) * 1998-04-15 2006-07-15 Lexigen Pharm Corp ENHANCEMENT OF ANTIBODY-CYTOKINE-FUSION PROTEIN-MEDIATED IMMUNE RESPONSE BY CO-ADMINISTRATION WITH AN ANGIOGENESIS HIBITOR
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (en) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Complexes of antibodies with some cytokines
AU7825500A (en) * 1999-10-07 2001-04-23 Pharmacia Corporation Inhibition enzyme linked immunosorbent assay (iELISA) for the detection and quantification of antibodies in biological samples
JP2003514552A (en) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Erythropoietin morphology with improved properties
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
JP5179689B2 (en) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Enhancing the half-life of antibody-based fusion proteins in the circulation
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
DK1294401T3 (en) * 2000-06-29 2007-10-08 Merck Patent Gmbh Improvement of antibody / cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake preparations
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
KR20030046411A (en) * 2000-09-08 2003-06-12 그리폰 테라퓨틱스, 인코포레이티드 'Pseudo'-Native Chemical Ligation
CA2440221C (en) * 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PL205352B1 (en) * 2001-05-03 2010-04-30 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US7332158B2 (en) * 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
RU2366664C2 (en) * 2002-12-17 2009-09-10 Мерк Патент Гмбх Humanised antibody (h14,18) based on mouse antibody 14,18, contacting gd2, and its fusion with il-2
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2006005360A1 (en) * 2004-07-12 2006-01-19 Sorin Group Italia S.R.L. Devices and methods for growing human cells
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP5137821B2 (en) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド PEGylated G-CSF polypeptide and method for producing the same
WO2007044115A2 (en) * 2005-08-02 2007-04-19 Planet Biotechnology, Inc. Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
ES2384055T3 (en) * 2005-12-30 2012-06-28 Merck Patent Gmbh Variants of interleukin-12p40 with improved stability
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
US8507221B2 (en) * 2007-09-21 2013-08-13 Cadila Healthcare Limited Process for the expression of peptides of interest using GCSF as a fusion partner
WO2011151716A1 (en) 2010-06-04 2011-12-08 Lupin Limited Process for the purification of recombinant human il-11

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JP2540509B2 (en) * 1984-07-06 1996-10-02 サンド・アクチエンゲゼルシヤフト Lymphokine production and purification
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
JPS63500636A (en) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 DNA encoding multipotent granulocyte colony stimulating factor
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4877729A (en) * 1986-07-14 1989-10-31 Genetics Institute, Inc. Recombinant DNA encoding novel family of primate hematopoietic growth factors
US5032395A (en) * 1986-07-14 1991-07-16 Genetics Institute, Inc. Method of inducing leukocytosis with a combination of IL-3 and GM-CSF
GR871029B (en) * 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
EP0275598B1 (en) * 1986-12-16 1998-01-07 Gist-Brocades N.V. Molecular cloning and expression of human IL-3
PT86381B (en) * 1986-12-16 1990-11-20 Gist Brocades Nv MOLECULAR AND EXPRESSION CLONING PROCESS OF HUMAN INTERLEUKIN-3 (IL-3)
AU1496688A (en) * 1987-01-20 1988-08-10 Immunex Corporation Human interleukin-3 proteins
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
GB2210883B (en) * 1987-10-08 1992-01-02 British Bio Technology Synthetic interleukin-3 gene
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
WO1990001039A1 (en) * 1988-07-20 1990-02-08 Immunex Corporation Nonglycosylated human interleukin-3 compositions
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
NZ232913A (en) * 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5128450A (en) * 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
US5516512A (en) * 1989-08-14 1996-05-14 Gist-Brocades, N.V. N- and C-terminal truncation and deletion mutants of human interleukin-3
DK0413383T3 (en) * 1989-08-14 1997-07-07 Gist Brocades Nv Mutants of human interleukin-3.
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
ES2055445T3 (en) * 1989-08-22 1994-08-16 Immunex Corp FUSION PROTEINS INCLUDING GM-CSF AND IL-3.
US5108910A (en) * 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
JPH03236400A (en) * 1990-02-09 1991-10-22 Kirin Brewery Co Ltd Chemically modified polypeptide and use thereof
JPH0463595A (en) * 1990-04-03 1992-02-28 Kirin Brewery Co Ltd Human interleukin 3 derivative
CA2089553C (en) * 1990-08-29 2000-06-27 Paul Schendel Multidomain hematopoiesis stimulators
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
DE4030850A1 (en) * 1990-09-29 1992-04-02 Henkel Kgaa Pasty bleaching agent compsn. - comprising perborate mono:hydrate in liq. medium comprising addn. prod. of ethylene oxide with long chain satd. alcohol
AU1372692A (en) * 1991-02-08 1992-09-07 Immunex Corporation Method of inhibiting replication of hiv in macrophages
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
JPH07501520A (en) * 1991-10-07 1995-02-16 メドベット　サイエンス　プロプライエタリー　リミテッド Human IL-3 variants
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
EP1283264A3 (en) * 1992-11-24 2004-03-10 G.D. Searle & Co. Interleukin-3 (IL-3) mutant polypeptides
US5667149A (en) * 1995-07-03 1997-09-16 Foster Wheeler Energy Corporation Solids pulverizer mill and process utilizing interactive air port nozzles

Also Published As

Publication number Publication date
CA2182483C (en) 2002-04-02
US6074639A (en) 2000-06-13
DE69530374D1 (en) 2003-05-22
AU700220B2 (en) 1998-12-24
DK0742796T3 (en) 2003-08-11
WO1995021197A1 (en) 1995-08-10
AU1680595A (en) 1995-08-21
ES2197191T3 (en) 2004-01-01
US5738849A (en) 1998-04-14
US5858347A (en) 1999-01-12
EP0742796A1 (en) 1996-11-20
DE69530374T2 (en) 2003-12-18
US6132991A (en) 2000-10-17
PT742796E (en) 2003-08-29
JPH09508524A (en) 1997-09-02
EP1323737A2 (en) 2003-07-02
EP0742796B1 (en) 2003-04-16
NZ279624A (en) 1998-05-27
ATE237641T1 (en) 2003-05-15
EP1323737A3 (en) 2003-10-15
HK1013655A1 (en) 1999-09-03

Similar Documents

Publication Publication Date Title
CA2182483A1 (en) Il-3 variant hematopoiesis fusion protein
EP1482044A3 (en) Multivariant IL-3 hematopoiesis fusion protein
ES2180624T3 (en) CO-ADMINISTRATION OF MUTANTS OF INTERLEUQUINA-3 WITH STIMULATING FACTORS OF COLONIES.
EP0442724A3 (en) Modified hil-6
CA2379388A1 (en) Immunoglobulin fusion proteins
CA2219988A1 (en) Cd16-ii variants
AU5670994A (en) Interleukin-3 (il-3) mutant polypeptides
CA2193993A1 (en) New hil-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
EP1090645A3 (en) Oral delivery of chemically modified proteins
EP0218531A3 (en) Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
EP0810285A3 (en) Mutants of human Interleukin-3
DK0742720T3 (en) Co-administration of interleukin-3 mutant polypeptides with CSFs to produce multi-lineage hematopoietic cells
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
CA2163805A1 (en) Novel activating factor of leukocytes
AU4636897A (en) Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses
ES2033212A6 (en) Ancrod proteins, their production and use.
ATE291629T1 (en) EXPRESSION SYSTEM FOR SECRETION OF BIOACTIVE HUMAN GRANULOCYTE MACROPHAGEM COLONITY STIMULATING FACTOR (GM-CSF) AND OTHER HETEROLOGUE PROTEINS FROM STREPTOMYCES
WO1992001794A3 (en) Ancrod-like proteins, their preparation and their use
WO2000027881A3 (en) Human interleukin 10 mutant proteins
Kuriya et al. A novel megakaryocyte potentiator produced by MC-1 human lung cancer cell line
Moreau et al. CHARACTERIZATION OF A FACTOR PRODUCED BY HUMAN ALLOREACTIVE T-CELL CLONES
Chensue Daniel G. Remick, Wendy E. Scales, and Steven L. Kunkel Department of Pathology The University of Michigan Medical School Ann Arbor, Michigan Stephen W. Chensue

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20090126